STERIS (STE)

STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.

STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.

Examine Steris' (STE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Steris plc remains a Strong Buy with a fair value of $281, supported by robust organic growth and margin expansion. The Trump administration's push to reshore pharma manufacturing could be a major tai...

STERIS plc (NYSE:STE ) Q4 2025 Results Conference Call May 15, 2025 9:00 AM ET Company Participants Julie Winter - Investor Relations Mike Tokich - Senior Vice President and Chief Financial Officer Da...

STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.

Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street es...

Steris (STE) came out with quarterly earnings of $2.74 per share, beating the Zacks Consensus Estimate of $2.59 per share. This compares to earnings of $2.41 per share a year ago.

Medical equipment maker Steris forecast annual profit above analysts' estimate on Wednesday, banking on strength in its biggest segment that sells sterilization products, sending its shares up more th...

Medical equipment maker Steris (STE) on Wednesday afternoon reported fiscal fourth-quarter 2025 financial results. A summary of its key numbers is below.